Principia Biopharma Inc. PRNB was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 17.7% in the past one-month time frame.
The company has seen one positive estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Principia Biopharma. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Principia Biopharma currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Principia Biopharma Inc. Price
Principia Biopharma Inc. price | Principia Biopharma Inc. Quote
A better-ranked stock in the Medical - Biomedical and Genetics industry is Applied Therapeutics Inc APLT, holding a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Principia Biopharma Inc. (PRNB) : Free Stock Analysis Report
Applied Therapeutics Inc. (APLT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research